HLA-DRB1 antibody (AA 26-100) (HRP)

Catalog No. ABIN6987790

Product Details anti-HLA-DRB1 Antibody (HRP)

Target: HLA-DRB1 (Major Histocompatibility Complex, Class II, DR beta 1 (HLA-DRB1))

Binding Specificity: AA 26-100

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This HLA-DRB1 antibody is conjugated to HRP

Application: Western Blotting (WB)

Cross-Reactivity: Human

Purification: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human HLA-DR/HLA DRB1

Isotype: IgG

Application Details

Application Notes: WB 1:300-5000

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Expiry Date: 12 months

Target Details for HLA-DRB1

Target: HLA-DRB1 (Major Histocompatibility Complex, Class II, DR beta 1 (HLA-DRB1))

Alternative Name: HLA-DR/HLA DRB1 (HLA-DRB1 Products)

Synonyms: MGC108235 antibody, DRB1 antibody, DRw10 antibody, HLA-DR1B antibody, HLA-DRB antibody, SS1 antibody, major histocompatibility complex, class II, DR beta 1 antibody, hla-drb1 antibody, HLA-DRB1 antibody

Background:

Synonyms: DR alpha chain precursor, DRB1, DRB4, HLA class II histocompatibility antigen, HLA class II histocompatibility antigen DR alpha chain, HLA DR1B, HLA DR3B, HLA DRA, HLA DRA1, HLA DRB3, HLA DRB4, HLA DRB5, HLADR4B, HLADRA1, HLADRB, Major histocompatibility complex class II DR alpha, Major histocompatibility complex class II DR beta 1, Major histocompatibility complex class II DR beta 3, Major histocompatibility complex class II DR beta 4, Major histocompatibility complex class II DR beta 5, MGC117330, MHC cell surface glycoprotein, MHC class II antigen DRA, MHC II, DRA_HUMAN.

Background: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments.

Gene ID: 3122

UniProt: P01903

Pathways: TCR Signaling, Positive Regulation of Peptide Hormone Secretion, Production of Molecular Mediator of Immune Response, CXCR4-mediated Signaling Events, Cancer Immune Checkpoints